Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% Equity-to-Asset is 0.84 as of Mar. 2026, which is 1% above its 10-year median of 0.83. The stock has 1 warning sign investors should review. Among 211 Medical Diagnostics & Research companies, Invitro International ranks better than 88.15% on this metric.
The historical rank and industry rank for Invitro International's Equity-to-Asset or its related term are showing as below:
IVRO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.81 Med: 0.83 Max: 0.84
Current: 0.84
During the past 9 years, the highest Equity to Asset Ratio of Invitro International was 0.84. The lowest was 0.81. And the median was 0.83.
IVRO's Equity-to-Asset is ranked better than 88.15% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs IVRO: 0.84
Invitro International (OTCPK:IVRO) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Invitro International Equity-to-Asset Related Terms
Invitro International Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Invitro International's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVRO vs IDTA, PRPH, NSTM: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Invitro International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Invitro International's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Invitro International's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a Equity-to-Asset of 0.84 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Invitro International and its competitors. This is near median its historical median of 0.83. Over the past decade, Invitro International's Equity-to-Asset has ranged from 0.81 to 0.84. According to the industry distribution chart, Invitro International ranks #25 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 11.8%.
Is Invitro International's Equity-to-Asset too high?
Invitro International's current Equity-to-Asset of 0.84 is near median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 0.84. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Invitro International's value of 0.84 is 42.4% above this industry median. Based on the distribution chart, Invitro International ranks #25 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's Equity-to-Asset compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #25 out of 211 companies for Equity-to-Asset. This places Invitro International in the top 12% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.59. Invitro International's value of 0.84 is 42.4% above this benchmark. Historically, Invitro International's own Equity-to-Asset has ranged from 0.81 to 0.84 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 0.59, Invitro International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Equity-to-Asset of 0.84 is 42.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Equity-to-Asset is 0.84, which is near median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Equity-to-Asset is 0.84, which is near median its 10-year median of 0.83 and 42.4% above the Medical Diagnostics & Research industry median of 0.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Invitro International (IVRO), the current Equity-to-Asset is 0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
